Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain

Adherence; Antiretroviral therapy; HIV

Detalles Bibliográficos
Autores: Moreno, Santiago, Rivero Román, Antonio, Ventayol, Pere, Torralba, Miguel, Schroeder, Melanie, Falcó, Vicenç
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/10341
Acceso en línea:https://hdl.handle.net/11351/10341
http://hdl.handle.net/11351/10341
Access Level:acceso abierto
Palabra clave:Infeccions per VIH - Tractament
Antiretrovirals - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos::antirretrovirales
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
id ES_cf93983cd3d4e23d9ffe7918f0b29f72
oai_identifier_str oai:recercat.cat:11351/10341
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
title Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
spellingShingle Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
Moreno, Santiago
Infeccions per VIH - Tractament
Antiretrovirals - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos::antirretrovirales
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
title_short Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
title_full Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
title_fullStr Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
title_full_unstemmed Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
title_sort Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
dc.creator.none.fl_str_mv Moreno, Santiago
Rivero Román, Antonio
Ventayol, Pere
Torralba, Miguel
Schroeder, Melanie
Falcó, Vicenç
author Moreno, Santiago
author_facet Moreno, Santiago
Rivero Román, Antonio
Ventayol, Pere
Torralba, Miguel
Schroeder, Melanie
Falcó, Vicenç
author_role author
author2 Rivero Román, Antonio
Ventayol, Pere
Torralba, Miguel
Schroeder, Melanie
Falcó, Vicenç
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Moreno S] Hospital Ramón y Cajal CIBERINFEC, Universidad de Alcalá, IRYCIS, Madrid, Spain. [Rivero A] Hospital Reina Sofía, Córdoba, Spain. [Ventayol P] Hospital Son Espases, Palma, Spain. [Falcó V] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Torralba M] Hospital de Guadalajara, Guadalajara, Spain. [Schroeder M] ViiV Healthcare, Brentford, UK
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Infeccions per VIH - Tractament
Antiretrovirals - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos::antirretrovirales
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
topic Infeccions per VIH - Tractament
Antiretrovirals - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos::antirretrovirales
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
description Adherence; Antiretroviral therapy; HIV
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/10341
http://hdl.handle.net/11351/10341
url https://hdl.handle.net/11351/10341
http://hdl.handle.net/11351/10341
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Infectious Diseases and Therapy;12
https://doi.org/10.1007/s40121-023-00840-y
dc.rights.none.fl_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420095931940864
spelling Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in SpainMoreno, SantiagoRivero Román, AntonioVentayol, PereTorralba, MiguelSchroeder, MelanieFalcó, VicençInfeccions per VIH - TractamentAntiretrovirals - Ús terapèuticCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral AgentsOther subheadings::Other subheadings::/therapeutic useDISEASES::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV InfectionsOther subheadings::Other subheadings::Other subheadings::/drug therapyCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos::antirretroviralesOtros calificadores::Otros calificadores::/uso terapéuticoENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIHOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaAdherence; Antiretroviral therapy; HIVAdherència; Teràpia antiretroviral; VIHAdherencia; Terapia antirretroviral; VIHIntroduction Current antiretroviral therapies (ARTs) have improved outcomes for people living with HIV. However, the requirement to adhere to lifelong daily oral dosing may be challenging for some people living with HIV, leading to suboptimal adherence and therefore reduced treatment effectiveness. Treatment with long-acting (LA) ART may improve adherence and health-related quality of life. The objective of this study was to evaluate the cost-effectiveness of cabotegravir + rilpivirine (CAB+RPV) LA administered every 2 months (Q2M) compared with current ART administered as daily oral single-tablet regimens (STRs) from a Spanish National Healthcare System perspective. Methods A hybrid decision-tree and Markov state-transition model was used with pooled data from three phase III/IIIb trials (FLAIR, ATLAS, and ATLAS-2M) over a lifetime horizon, with health states defined by viral load and CD4+ cell count. Direct costs (in €) were taken from Spanish public sources from 2021 and several deterministic and probabilistic analyses were carried out. An annual 3% discount rate was applied to both costs and utilities. Results Over the lifetime horizon, CAB+RPV LA Q2M was associated with an additional 0.27 quality-adjusted life years (QALYs) and slightly greater lifetime costs (€4003) versus daily oral ART, leading to an incremental cost-effectiveness ratio of €15,003/QALY, below the commonly accepted €30,000/QALY willingness-to-pay threshold in Spain. All scenario analyses showed consistent results, and the probabilistic sensitivity analysis showed cost-effectiveness compared with daily oral STRs in 62.4% of simulations, being dominant in 0.3%. Conclusion From the Spanish National Health System perspective, CAB+RPV LA Q2M is a cost-effective alternative compared with the current options of daily oral STR regimens for HIV treatment.This study, including the journal’s Rapid Service fee, was funded by ViiV Healthcare, Durham, NC, USA.SpringerInstitut Català de la Salut[Moreno S] Hospital Ramón y Cajal CIBERINFEC, Universidad de Alcalá, IRYCIS, Madrid, Spain. [Rivero A] Hospital Reina Sofía, Córdoba, Spain. [Ventayol P] Hospital Son Espases, Palma, Spain. [Falcó V] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Torralba M] Hospital de Guadalajara, Guadalajara, Spain. [Schroeder M] ViiV Healthcare, Brentford, UKVall d'Hebron Barcelona Hospital Campus202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/10341http://hdl.handle.net/11351/10341Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésInfectious Diseases and Therapy;12https://doi.org/10.1007/s40121-023-00840-yAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/103412026-05-29T05:05:01Z
score 15,812429

Similares en LA Referencia